In the phase II program, tirzepatide was also shown to improve biomarkers for cardiovascular risk and to improve NASH (6365)
Tirzepatide showed higher average weight loss in SURMOUNT trials, while semaglutide has a very large GLP-1 evidence base
The amount of weight lost was the same for the participants taking GLP-1s or other weight loss drugs
This is the chemistry behind a rule you will see stated everywhere but explained nowhere
By purchasing, you confirm that you are at least 21 years of age, that you are a qualified researcher or professional acquiring this material for legitimate research use, and that you accept full responsibility for its safe handling, storage, and lawful use in accordance with all applicable regulations
Applicable Procedure Code: J3285